S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

monday.com (MNDY) Stock Forecast & Price Target

$178.07
-7.03 (-3.80%)
(As of 04/19/2024 08:51 PM ET)

monday.com Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$238.33
33.84% Upside
High Forecast$280.00
Average Forecast$238.33
Low Forecast$190.00
TypeCurrent Forecast
4/23/23 to 4/22/24
1 Month Ago
3/24/23 to 3/23/24
3 Months Ago
1/23/23 to 1/23/24
1 Year Ago
4/23/22 to 4/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
15 Buy rating(s)
13 Buy rating(s)
Hold
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$238.33$226.00$203.38$178.60
Predicted Upside33.84% Upside18.65% Upside26.98% Upside27.07% Upside
Get monday.com Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MNDY and its competitors with MarketBeat's FREE daily newsletter.

MNDY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MNDY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

monday.com Stock vs. The Competition

Typemonday.comComputer and Technology CompaniesS&P 500
Consensus Rating Score
2.80
2.58
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside33.84% Upside130.51% Upside11.94% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$277.00 ➝ $250.00+15.87%
4/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$260.00+20.69%
3/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$230.00 ➝ $270.00+18.42%
3/21/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$275.00+18.34%
3/5/2024Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $280.00+28.03%
2/26/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$280.00+34.68%
2/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$220.00 ➝ $240.00+10.29%
2/13/2024DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$190.00-12.17%
2/13/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$250.00+17.92%
2/13/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$230.00+8.49%
1/5/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$180.00 ➝ $230.00+33.64%
12/7/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$185.00 ➝ $200.00+14.36%
12/7/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$195.00+10.36%
8/15/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$180.00 ➝ $205.00+24.24%
8/15/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$215.00 ➝ $220.00+30.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:35 AM ET.

MNDY Price Target - Frequently Asked Questions

What is monday.com's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for monday.com stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for MNDY. The average twelve-month price prediction for monday.com is $238.33 with a high price target of $280.00 and a low price target of $190.00. Learn more on MNDY's analyst rating history.

Do Wall Street analysts like monday.com more than its competitors?

Analysts like monday.com more than other Computer and Technology companies. The consensus rating score for monday.com is 2.80 while the average consensus rating score for computer and technology companies is 2.58. Learn more on how MNDY compares to other companies.

Is monday.com being downgraded by Wall Street analysts?

Over the previous 90 days, monday.com's stock had 1 downgrade by analysts.

Does monday.com's stock price have much upside?

According to analysts, monday.com's stock has a predicted upside of 17.83% based on their 12-month stock forecasts.

What analysts cover monday.com?

Stock Ratings Reports and Tools

This page (NASDAQ:MNDY) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners